Financial Data and Key Metrics Changes - Q3 consolidated revenues increased by 5.7% year over year, reaching $1,060 million, with organic growth of 2% [5][25] - Non-GAAP earnings per share (EPS) grew by 15% year over year to $1.1, with free cash flow reported at $165 million [5][28] - Gross margin improved by 70 basis points to 67.3%, driven by efficiency gains and favorable foreign exchange [25] Business Line Data and Key Metrics Changes - CooperVision reported revenues of $718 million, reflecting a 6.3% increase and 2.4% organic growth, although results were below expectations due to declines in Clarity orders [6][9] - CooperSurgical posted revenues of $342 million, up 4.5% year over year, with fertility revenues growing 6% [20][21] - MyDay lenses showed double-digit growth, with MyDay Multifocal growing 20% [11][13] Market Data and Key Metrics Changes - EMEA region grew 14% or 6% organically, becoming CooperVision's largest revenue region globally [9] - The Americas grew 2% or 3% organically, while Asia Pac grew 1% but declined 5% organically due to Clarity pressure [9][10] - The overall contact lens market is expected to continue mid-single-digit growth, driven by a shift towards silicone hydrogel lenses [19] Company Strategy and Development Direction - The company aims to leverage strong MyDay momentum and upcoming product launches to gain market share [23][30] - Focus on operational excellence and disciplined cost management to support sustainable revenue growth [5][28] - Ongoing restructuring efforts to enhance efficiency and leverage IT upgrades [73][74] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in the contact lens market, particularly in Asia Pac, but remains optimistic about long-term growth in fertility and contact lenses [20][50] - Guidance for Q4 indicates expected organic growth of 2% to 4% for both CooperVision and CooperSurgical, factoring in potential headwinds [22][23] - Confidence in achieving $2 billion in free cash flow over the next three fiscal years, supported by improved operating margins [30][102] Other Important Information - The company repurchased $52 million worth of stock during the quarter, with approximately $164 million remaining under the repurchase plan [28] - Tariff impacts are expected to be lower than previously anticipated, with mitigation strategies in place [29][30] Q&A Session Summary Question: How does the core CVI portfolio compare to market growth for fiscal 2026? - Management indicated that the core portfolio has lagged the market but expects to be at least in line with market growth, with additional contributions from MySight [36][40] Question: Why is MyDay's success impacting Clarity? - Management noted that in some markets, Clarity and MyDay were viewed similarly, leading to a shift in orders towards MyDay [41][45] Question: What is the outlook for the contact lens market's growth? - Management acknowledged a slowdown in market growth but remains confident in the long-term fundamentals, including pricing and consumer trends [50][52] Question: What are the drivers for expected Q4 rebound in fertility? - Management highlighted improvements in genomics and consumables, along with anticipated investments from fertility clinics [110][114] Question: What is the situation with PARAGARD and market dynamics? - Management confirmed no new competitive launches but acknowledged declining volumes, offset by pricing strategies [117][119]

SARASOTA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced second quarter 2025 financial results. Q2 2025 Financial Highlights (all metrics compared to Q2 2024 unless otherwise noted) Revenue was $1,863,654, an increase of 1% co ...

Core Insights - NewGen has acquired advanced cytometry technology and assets, including 18 fully-constructed cell-sorting systems and six related patents, to enhance its market position and support U.S. expansion [1][2][4] - The U.S. fertility services market is growing, with over 432,000 IVF cycles performed in 2023, indicating a significant opportunity for NewGen's NewGenSort services [3][5] Company Developments - The acquisition builds on NewGen's earlier purchase of MicroSort technology, now rebranded as NewGenSort, which allows for precise separation of sperm cells based on chromosomal content [2][5] - NewGen anticipates that its U.S. operations could generate over $20 million in annual gross revenue once fully operational, based on conservative pricing and utilization assumptions [4] Market Context - The Society for Assisted Reproductive Technology reported an increase in IVF cycles from 389,993 in 2022 to 432,641 in 2023, with IVF births rising from 91,771 to 95,860 during the same period [3] - Each sorting system is projected to perform around four sorts per day, allowing NewGen to process over 25,000 sorts annually, which represents less than 6% of total U.S. IVF cycles [3][4] Strategic Vision - The CEO of NewGen emphasized that this acquisition is a significant milestone in the company's expansion strategy, aimed at meeting the growing demand for advanced fertility services in the U.S. market [5]

Core Viewpoint - NewGenDigital has entered into a Memorandum of Understanding with BNW Real Estate Development LLC to develop a strategic plot of land in Ras Al Khaimah, UAE, with an estimated potential net return of up to US$67 million from the project [1][4]. Group 1: Partnership Details - The MOU aims to negotiate a Joint Venture Agreement to form a special-purpose vehicle for the development of the plot [1]. - BNW is responsible for all construction and management costs, while NewGenDigital will contribute 36% of the land cost, estimated at about US$24 million [3]. - BNW will initially cover the remaining 64% of the land cost and any payments made on behalf of NewGenDigital will be deducted from its final entitlement [3]. Group 2: Financial Projections - A feasibility study by BNW estimates a net return of up to US$67 million for NewGenDigital, representing a 272% return on investment after accounting for costs [4]. - The projected sale price is estimated at AED3,000 per square foot (approximately US$817), with a total saleable area of 527,753 square feet [4]. - Consultant, construction, and administration costs are estimated at AED823 per square foot [4]. Group 3: Company Background - NewGen is a comprehensive fertility services provider in Asia, with clinics in Thailand, Cambodia, and Kyrgyzstan, offering a full suite of fertility treatments [6]. - The company aims to expand beyond its core fertility services through strategic partnerships like the one with BNW [5].

Core Viewpoint - INVO Fertility, Inc. announced a 1-for-3 reverse stock split to comply with Nasdaq's minimum bid price requirement, effective July 21, 2025 [1][3]. Group 1: Reverse Stock Split Details - The reverse stock split will convert every 3 shares of common stock into 1 share, rounding up any fractional shares [2]. - Post-split, the company will have approximately 928,272 shares issued and outstanding, with authorized shares adjusted to 1,388,888 [2]. Group 2: Company Overview - INVO Fertility is focused on expanding assisted reproductive technology (ART) care, operating fertility clinics, and distributing its proprietary INVOcell medical device [4]. - The INVOcell device allows fertilization and early embryo development to occur in vivo, offering a more natural and cost-effective alternative to traditional IVF [4].

Core Insights - INVO Fertility, Inc. is enhancing its fertility services through expanded clinical and embryology training support and improved pricing for its INVOcell technology, aiming to provide patient-centered care while expanding clinic operations [1][3][4] Company Overview - INVO Fertility focuses on the fertility market, operating two INVO Centers and one IVF clinic in the U.S., and aims to build, acquire, and operate more fertility clinics [6] - The company offers the INVOcell, the first FDA-cleared intravaginal culture system, which allows fertilization and early embryo development to occur within a woman's body, providing a more natural alternative to traditional IVF [2][6] Product and Technology - INVOcell delivers comparable pregnancy rates to conventional IVF while offering a more intimate and affordable experience for patients [2][8] - The company has secured a notice of allowance for a new patent from the U.S. Patent and Trademark Office, reinforcing its position as a technology innovator [4] Training and Support - INVO Fertility provides hands-on training and clinical support for embryologists and physicians to integrate the INVOcell solution into their practices [3] - The company is launching targeted educational campaigns to raise awareness of patient success rates with INVOcell, which are similar to those of conventional IVF [3] Market Positioning - INVOcell is positioned as an inclusive option for diverse family structures, including same-sex couples and single parents, and offers a streamlined lab workflow for clinics [8]

Core Insights - NewGenIvf Group Limited's subsidiary, NewGenDigital, has secured a strategic plot of land in Ras Al Khaimah, UAE, and is exploring the feasibility of issuing digital tokens tied to this plot as part of a blockchain asset digitization strategy [1][3] - The real estate project associated with the plot is projected to generate sales revenue exceeding US$400 million, indicating significant potential for financial returns [1][4] - The plot, measuring 110,400 sq. ft. with an estimated saleable area of approximately 527,750 sq. ft., is located in a prime beachfront area, benefiting from the region's economic growth and investor-friendly policies [2][4] Company Strategy - NewGenDigital aims to leverage Real World Asset (RWA) tokenization, which transforms physical assets like real estate into digital tokens, enhancing ownership management and liquidity [3] - The UAE's regulatory environment, including the establishment of the Ras Al Khaimah Digital Assets Oasis Free Zone and the Virtual Asset Regulatory Authority, supports NewGenDigital's blockchain initiatives [3] - The company's strategic move into the digital asset space aligns with its broader investment initiative of US$45 million in the UAE real estate market [1][3] Market Context - The Ras Al Khaimah region is poised for growth, particularly with the upcoming Wynn Al Marjan Island integrated resort set to open in early 2027, which is expected to further enhance the area's attractiveness for investment [2] - NewGenDigital's entry into the region is welcomed by local developers, indicating a collaborative environment for international brands and developers [4]

Core Viewpoint - INVO Fertility, Inc. has introduced Platelet-Rich Plasma (PRP) therapy at its Wisconsin Fertility Institute center, enhancing its fertility services and commitment to innovative patient care [1][3]. Group 1: PRP Therapy Overview - PRP therapy utilizes the body's growth factors to promote uterine lining growth and ovarian rejuvenation, potentially improving implantation rates and ovarian response [2]. - This treatment is particularly beneficial for women with specific fertility challenges, such as a thin uterine lining or diminished ovarian reserve, and serves as an alternative to egg donation or surrogacy [2]. Group 2: Company Strategy and Offerings - INVO Fertility focuses on expanding assisted reproductive technology (ART) care through building, acquiring, and operating fertility clinics, including INVO Centers that offer the intravaginal culture (IVC) procedure using the INVOcell medical device [4]. - The INVOcell device allows fertilization and early embryo development to occur in vivo, providing a more natural and affordable experience compared to traditional IVF, with comparable results at a lower cost [4].

Core Viewpoint - INVO Fertility, Inc. is urging shareholders to vote online for the upcoming annual meeting on June 25, 2025, with the Board recommending a "FOR" vote on all proposals to support the company's growth strategies [1][2]. Company Overview - INVO Fertility is focused on expanding assisted reproductive technology (ART) care, primarily through building, acquiring, and operating fertility clinics, including INVO Centers that utilize the INVOcell medical device [5][7]. - The company currently operates two INVO Centers and one IVF clinic in the United States, and it is engaged in the sale and distribution of INVOcell technology to third-party clinics [5][7]. Growth Strategies - The CEO highlighted a robust pipeline of potential transactions for complementary and revenue-generating services and technologies, aiming to leverage the company's public platform for favorable transactions [2]. - The company is focused on acquiring established, profitable fertility clinics and expanding its INVOcell technology to capitalize on favorable market trends and policy developments [2]. Voting Information - Shareholders of record as of May 21, 2025, are entitled to vote at the Annual Meeting, and various voting methods are available, including online, by mail, and by phone [3][6]. - The Annual Meeting will be conducted virtually, allowing shareholders to submit questions and vote online [4].

Core Viewpoint - INVO Fertility, Inc. is expanding its telehealth capabilities at the Wisconsin Fertility Institute to enhance access to fertility care for prospective parents, particularly in underserved areas [1][5]. Group 1: Telehealth Expansion - The telehealth platform allows patients to connect with fertility specialists from home, providing personalized assessments and treatment planning through secure virtual consultations [3][4]. - This initiative aims to break down geographic barriers, making expert fertility care more accessible and convenient for individuals and couples [4][5]. Group 2: Service Reach and Accessibility - The expansion is expected to significantly broaden the reach of Wisconsin Fertility Institute, especially for those in rural areas facing challenges in accessing specialized fertility care [5]. - The integration of telehealth with in-clinic procedures is designed to help families navigate the complexities of fertility treatment with greater confidence and ease [5]. Group 3: Company Overview - INVO Fertility focuses on expanding assisted reproductive technology (ART) care through the establishment and operation of fertility clinics, including the innovative INVOcell medical device [7]. - The company operates two INVO Centers and one IVF clinic in the U.S., and continues to distribute its INVOcell technology to third-party clinics [7].